Roche’s Q3 sales were marginally shy of the estimates at CHF12.48bn (vs our estimate of CHF12.56bn and the consensus estimate of CHF12.64bn), primarily due to the uninspiring performance of the mature drugs in the US. Nine months’ revenue came in at CHF37.5bn. These numbers represented (at CER) growth of 3% for the quarter and 4% for 9m. Forex had a positive impact of 150bp in Q3. The Pharma segment was up by 2% (vs 5% in Q2) to CHF9.7bn while the diagnostics business continued it
25 Oct 2016
Nothing wrong but sentiment in a dull stretch
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nothing wrong but sentiment in a dull stretch
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
25 Oct 2016 -
Author:
Kamla Singh -
Pages:
4
Roche’s Q3 sales were marginally shy of the estimates at CHF12.48bn (vs our estimate of CHF12.56bn and the consensus estimate of CHF12.64bn), primarily due to the uninspiring performance of the mature drugs in the US. Nine months’ revenue came in at CHF37.5bn. These numbers represented (at CER) growth of 3% for the quarter and 4% for 9m. Forex had a positive impact of 150bp in Q3. The Pharma segment was up by 2% (vs 5% in Q2) to CHF9.7bn while the diagnostics business continued it